1. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
- Author
-
Hill, Joshua A, Martens, Michael J, Young, Jo-Anne H, Bhavsar, Kavita, Kou, Jianqun, Chen, Min, Lee, Lik Wee, Baluch, Aliyah, Dhodapkar, Madhav V, Nakamura, Ryotaro, Peyton, Kristin, Howard, Dianna S, Ibrahim, Uroosa, Shahid, Zainab, Armistead, Paul, Westervelt, Peter, McCarty, John, McGuirk, Joseph, Hamadani, Mehdi, and DeWolf, Susan
- Subjects
HEMATOPOIETIC stem cell transplantation ,IMMUNIZATION ,RESEARCH funding ,HUMAN beings ,SCIENTIFIC observation ,IMMUNOGLOBULINS ,COVID-19 vaccines ,CELLULAR therapy ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,LONGITUDINAL method ,RESEARCH - Abstract
Background The optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether humoral and cellular responses after SARS-CoV-2 vaccination differ if initiated <4 months versus 4–12 months after cellular therapy. Methods We conducted a multicenter, prospective, observational study at 30 cancer centers in the United States. SARS-CoV-2 vaccination was administered as part of routine care. We obtained blood prior to and after vaccinations at up to 5 time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2–specific T-cell receptors, in a subgroup. Results We enrolled 466 allogeneic hematopoietic cell transplantation (HCT) (n = 231), autologous HCT (n = 170), and chimeric antigen receptor T-cell (CAR-T-cell) therapy (n = 65) recipients between April 2021 and June 2022. Humoral and cellular responses did not significantly differ among participants initiating vaccinations <4 months versus 4–12 months after cellular therapy. Anti-S IgG ≥2500 U/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T-cell recipients, respectively. SARS-CoV-2–specific T-cell responses were attained in 57%, 83%, and 58%, respectively. Pre–cellular therapy SARS-CoV-2 infection or vaccination and baseline B-cell count were key predictors of post–cellular therapy immunity. Conclusions These data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation 3 to 4 months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T-cell therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF